Pfizer and BioNTech have said clinical trial results showed their coronavirus vaccine was “safe, well tolerated” and produced a “robust” immune response in children aged five to 11, adding that they would seek regulatory approval shortly, Reuters reports.
The vaccine would be administered at a lower dosage than for people aged 12 and over, the companies said in a statement.
They said they would submit their data to regulatory bodies in the European Union, the United States and around the world “as soon as possible”.
